At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
WB-011 +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
In Brief
A clinical study evaluating WB-011, Placebo, and 1 other intervention for Diabetes Type 2 and Diabetes Mellitus. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This 5-week, double-blind, placebo-controlled, 2x2 crossover pilot study investigate the potential of collecting robust, real-time clinical study measures of glucose levels using Abbott Freestyle Libre Continuous Glucose Monitoring devices associated with a smartphone application
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Type 2, Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
Primary CompletionApr 2018
Study CompletionJun 2018
First PostedJun 2020
TodayJul 2026
First PostedJun 11, 2020
Enrollment StartMar 15, 2018
Primary CompletionApr 29, 2018
Study CompletionJun 29, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.1 years ago
Interventions
WB-011other
WB-011 medical food product.
Placeboother
Placebo Capsules identical to those containing WB-011.
Continuous Glucose Monitordevice
Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.